MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Eli Lilly and Co.

Deschisă

SectorSănătate

801.78 -2.8

Rezumat

Modificarea prețului

24h

Curent

Minim

796.87

Maxim

824

Indicatori cheie

By Trading Economics

Venit

3.4B

4.4B

Vânzări

2.1B

14B

P/E

Medie Sector

73.734

73.239

EPS

5.32

Randament dividend

0.72

Marjă de profit

32.586

Angajați

47,000

EBITDA

1.2B

6.1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+23.83% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.72%

3.06%

Următoarele câștiguri

1 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-8B

777B

Deschiderea anterioară

804.58

Închiderea anterioară

801.78

Sentimentul știrilor

By Acuity

46%

54%

152 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 mar. 2025, 15:54 UTC

Top știri

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb. 2025, 15:14 UTC

Top știri

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 feb. 2025, 14:30 UTC

Top știri

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 feb. 2025, 12:00 UTC

Top știri

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb. 2025, 10:30 UTC

Top știri

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb. 2025, 16:16 UTC

Top știri
Câștiguri

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb. 2025, 14:56 UTC

Câștiguri

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 feb. 2025, 14:32 UTC

Market Talk
Câștiguri

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 feb. 2025, 13:18 UTC

Top știri
Câștiguri

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6 feb. 2025, 12:24 UTC

Câștiguri

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6 feb. 2025, 12:01 UTC

Câștiguri

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6 feb. 2025, 11:49 UTC

Câștiguri

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6 feb. 2025, 11:48 UTC

Câștiguri

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6 feb. 2025, 11:47 UTC

Câștiguri

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6 feb. 2025, 11:46 UTC

Câștiguri

Eli Lilly 4Q Gross Margin 82.2% >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly Sees FY Rev $58B-$61B >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Net $4.41B >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q EPS $4.88 >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Rev $13.53B >LLY

6 feb. 2025, 11:45 UTC

Câștiguri

Eli Lilly 4Q Adj EPS $5.32 >LLY

5 feb. 2025, 21:23 UTC

Top știri

Eli Lilly's Results Already Disappointed the Street. More Details Come Thursday. -- Barrons.com

5 feb. 2025, 12:02 UTC

Câștiguri

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb. 2025, 12:00 UTC

Top știri

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

23.83% sus

Prognoză pe 12 luni

Medie 1,022.71 USD  23.83%

Maxim 1,146 USD

Minim 900 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

18

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

824.76 / 836.29Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

152 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.